Comparison of efficacy of buccal versus vaginal misoprostol in first trimester induced abortion

Nida Khan, Anita M. Kant, Pooja C. Thukral, Mohammad Saquib


Background: To compare the effectiveness, side effects, and patient satisfaction of buccal versus vaginal misoprostol administration in first trimester abortions.

Methods: Women opting for first trimester abortion received oral Mifepristone followed 48 hours latermisoprostol. Group A received Misoprostol via buccal route whereas group B received Misoprostol vaginally. A comparative analysis using SPSS was done.

Results: Giving 800µg Misoprostol by either buccal or vaginal route after oral Mifepristone have comparable efficacy in terms of complete abortion rate (96% in buccal group versus 98% in vaginal group; p value = 0.495), failure rate being statistically similar (4% versus 2%). Drug abortion interval was comparable in the two groups. (11.16 hour in buccal group and 12.32 hours in vaginal group). Few side effects like nausea and vomiting, shivering, diarrohea was significantly higher with vaginal Misoprostol while abdominal cramps, altered taste were found more with the buccal group.

Conclusions: Buccal Misoprostol is comfortable and easier to administer when compared to other routes and it has potential to be developed as a self-administered regimen. Buccal Misoprostol is as efficacious as vaginal Misoprostol with significantly lesser side effects up to 7 weeks of period of gestation.


Abortions, Buccal, Comparative analysis, First trimester, Misoprostol, Vaginal

Full Text:



Singh S, Wulf D, Hussain R, Bankole A, Sedgh G. Abortion worldwide: A decade of uneven Progress. New York: Guttmacher Institute; 2009.

India. Go . The Medical Termination of Pregnancy Act, (Act No 34, 1971) and MTP rules and regulations, Vide G.S.R. 2543, 1975. New Delhi: Gazette of India; 1975.

Lohr PA, Reeves MF, Hayes JL. Oral mifepristone and buccal misoprostol administered simultaneously for abortion: a pilot study. Contracept. 2007;76:215-20.

Population Council, International Federation of Gynecology and Obstetrics (FIGO), and Reproductive Health Supplies Coalition. “2013 Statement from the Bellagio Group on LARCs: Long-Acting Reversible Contraception in the Context of Full Access, Full Choice. 2013. Available At Consensus.pdf.

Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005;72(5):328-32.

Geetika G, Navneet T, Alka S. Buccal versus vaginal misoprostol administration for the induction of first and second trimester abortions. J Obst Gynecol. 2015;2:111-6.

Peña M, Dzuba IG, Smith PS, Mendoza LJ, Bousiéguez M, Martínez ML. Efficacy and acceptability of a mifepristone - misoprostol combined regimen for early induced abortion among women in Mexico City. Int J Gynec Obst. 2014;04:12.

Li YT, Hsieh JC, Hou GQ, Chen TH, Chu YC, Lin TC, et al. Simultaneous use of mifepristone and misoprostol for early pregnancy termination. Taiwan J Obstet Gynecol. 2011;50(1):11-4.

Alam A, Bracken H, Johnston HB, Raghavan S, Islam N, Winikoff B. Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh. Int Perspect Sex Reprod Health. 2013;39(2):79-87.

Goldstone P, Michelson J, Williamson E. Early medical abortion using low - dose mifepristone followed by buccal misoprostol. Medical J Austrailia. 2012;197(5):282-6.